[1]
Nucleic acid therapeutics are third most emerging technology and substrate after small-molecules and antibodies.
Simple, fast, and cost-effective.
RNA therapeutics doesn’t induce mutagenesis such as DNA does.
Conditional execution have not been figured out. Most DNA/RNA therapeutics are delivered to their action site. Lipid Nano particles (LNPs) are also a delivery vehicle.
Alternative strategy is to enhance specificity by incorporating computing into the circuits—triggers as ‘input’, programming modalities as the ‘transducer’ and the output as the ‘effector’.